Clinical trials
Cardiomyopathy, Hypertrophic trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 8 |
| Completed | 7 |
| Unknown status | 5 |
| Active, not recruiting | 3 |
| Terminated | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bristol-Myers Squibb | 4 |
| Cytokinetics | 3 |
| Heidelberg University | 2 |
| Wuerzburg University Hospital | 2 |
| Deutsches Herzzentrum Muenchen | 1 |
| German Heart Institute | 1 |
| Gilead Sciences | 1 |
| Imbria Pharmaceuticals, Inc. | 1 |
| Johann Wolfgang Goethe University Hospital | 1 |
| Lexicon Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiomyopathy, Hypertrophic | 26 |
| Cardiomyopathies | 5 |
| Cardiomyopathy, Dilated | 5 |
| Heart Failure | 4 |
| Arrhythmogenic Right Ventricular Dysplasia | 3 |
| Amyloidosis | 2 |
| Fabry Disease | 2 |
| Lysosomal Storage Diseases | 2 |
| Rare Diseases | 2 |
| Amyloid Neuropathies, Familial | 1 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.